MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

Search

Axsome Therapeutics Inc

Cerrado

SectorSalud

106.94 0.65

Resumen

Variación precio

24h

Actual

Mínimo

106.25

Máximo

109

Métricas clave

By Trading Economics

Ingresos

-10M

-75M

Ventas

14M

119M

BPA

-1.54

Margen de beneficio

-63.075

Empleados

683

EBITDA

-10M

-71M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+65.49% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.1B

5.1B

Apertura anterior

106.29

Cierre anterior

106.94

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Axsome Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2025, 23:27 UTC

Principales Noticias

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28 abr 2025, 23:07 UTC

Principales Noticias

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28 abr 2025, 23:03 UTC

Ganancias

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28 abr 2025, 23:47 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28 abr 2025, 23:17 UTC

Ganancias

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28 abr 2025, 23:17 UTC

Ganancias

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28 abr 2025, 23:13 UTC

Ganancias

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28 abr 2025, 23:08 UTC

Ganancias

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28 abr 2025, 23:04 UTC

Ganancias

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28 abr 2025, 23:00 UTC

Ganancias

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28 abr 2025, 22:57 UTC

Principales Noticias

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28 abr 2025, 22:55 UTC

Ganancias

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28 abr 2025, 22:52 UTC

Ganancias

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28 abr 2025, 22:46 UTC

Ganancias

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Comparación entre iguales

Cambio de precio

Axsome Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

65.49% repunte

Estimación a 12 meses

Media 175.87 USD  65.49%

Máximo 216 USD

Mínimo 133 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Axsome Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

18 ratings

18

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

104.22 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.